AR-110 , has demonstrated to be superior to Zytiga and Xtandi for cancer cell to develop resistance to.
In preclinical studies, ARV-110 reduced AR levels by 95-98% in several prostate cancer cell lines. Additionally, in a mouse model inhibited tumor growth by up to 100%.
AR-110 may be available in a year or so, I may not be.
It would be great if ARV-110 was available soon but if it's just starting Phase I trials it may be many more years before it's available. The average time for a drug to get through all clinical trials and FDA approval is approximately 10 years. However, the FDA is looking at reforms that could greatly speed up the clinical trial process. Let's hope they succeed. But until then one could always pursue the "right to try" once this drug completes Phase I if they have failed all other drug options.
“We hope ARV-110 will deliver a much-needed new therapeutic option for patients, and we expect to dose our first patient in the first quarter of 2019.”
That would be the first patient accepted into the clinical trial Phase I. You should check with your MO as you may qualify for the clinical trial. It's worth pursuing.
Read your past posts Bob. We all pray that you are available a year from now. God Bless.
Looks like ARV 110 started with its 1st patient in a clinical trial. I cannot find out any information about it or where it is. Does anyone know anything about it?
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.